Who owns Black Diamond Therapeutics Inc?
- Ticker: BDTX
- CUSIP Number: 09203e105
Tip: Access positions for across all investors
Analyze quarterly positions in Black Diamond Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Black Diamond Therapeutics stock
Who bought or sold Black Diamond Therapeutics Inc this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
Bellevue Group | 8.5M | $43M | 0% | Mar 2024 |
|
T. Rowe Price Investment Management | 6.7M | $34M | 212% | Mar 2024 |
|
NEA Management Company | 4.4M | $23M | 0% | Mar 2024 |
|
RA Capital Management | 3.5M | $18M | 0% | Mar 2024 |
|
Vanguard Group | 1.9M | $9.7M | -2% | Mar 2024 |
|
Tang Capital Management | 1.6M | $8.1M | -11% | Mar 2024 |
|
BlackRock | 1.4M | $7.0M | -1% | Mar 2024 |
|
Artal Group | 1.0M | $5.3M | -49% | Mar 2024 |
|
Laurion Capital Management | 878k | $4.5M | 100% | Mar 2024 |
|
Kennedy Capital Management | 717k | $3.6M | -3% | Mar 2024 |
|
Blue Owl Capital Holdings | 695k | $3.5M | 0% | Mar 2024 |
|
Millennium Management | 546k | $2.8M | 348% | Mar 2024 |
|
Boxer Capital | 506k | $2.6M | 0% | Mar 2024 |
|
Susquehanna International | 446k | $2.3M | 16% | Mar 2024 |
|
Geode Capital Management | 383k | $1.9M | 18% | Mar 2024 |
|
Two Sigma Investments | 358k | $1.8M | -3% | Mar 2024 |
|
Goldman Sachs Group | 333k | $1.7M | 625% | Mar 2024 |
|
Verition Fund Management | 329k | $1.7M | -81% | Mar 2024 |
|
Connor, Clark & Lunn Investment Management | 315k | $1.6M | 100% | Mar 2024 |
|
UBS O'Connor | 257k | $1.3M | 100% | Mar 2024 |
|
Jane Street | 251k | $1.3M | 353% | Mar 2024 |
|
Bridgeway Capital Management | 173k | $877k | 37% | Mar 2024 |
|
Qube Research & Technologies | 173k | $875k | 5816% | Mar 2024 |
|
Squarepoint Ops | 171k | $869k | 18% | Mar 2024 |
|
Acadian Asset Management | 171k | $864k | 100% | Mar 2024 |
|
Barclays | 167k | $847k | 0% | Mar 2024 |
|
Stifel Financial | 148k | $752k | 33% | Mar 2024 |
|
Hrt Financial | 125k | $634k | 100% | Mar 2024 |
|
Newtyn Management | 125k | $634k | -55% | Mar 2024 |
|
Man Group | 120k | $606k | 100% | Mar 2024 |
|
ExodusPoint Capital Management | 116k | $586k | 100% | Mar 2024 |
|
Citigroup | 113k | $570k | 108% | Mar 2024 |
|
Dimensional Fund Advisors | 112k | $566k | 1% | Mar 2024 |
|
Northern Trust | 104k | $527k | 50% | Mar 2024 |
|
Foundations Investment Advisors | 97k | $489k | 100% | Mar 2024 |
|
Two Sigma Advisers | 96k | $488k | -6% | Mar 2024 |
|
Marathon Trading Investment Management | 94k | $479k | 100% | Mar 2024 |
|
TD Asset Management | 71k | $359k | 100% | Mar 2024 |
|
Castleview Partners | 64k | $324k | 100% | Mar 2024 |
|
Morgan Stanley | 59k | $299k | 167% | Mar 2024 |
|
CornerCap Investment Counsel | 49k | $247k | -41% | Mar 2024 |
|
Cubist Systematic Strategies | 44k | $222k | 193% | Mar 2024 |
|
Jump Financial | 39k | $109k | 245% | Dec 2023 |
|
Point72 Asia | 37k | $188k | 100% | Mar 2024 |
|
Balyasny Asset Management | 35k | $177k | 100% | Mar 2024 |
|
Brevan Howard Capital Management | 29k | $147k | 100% | Mar 2024 |
|
Y-Intercept | 28k | $140k | 100% | Mar 2024 |
|
Credit Suisse | 26k | $130k | 0% | Mar 2024 |
|
Citadel Advisors | 24k | $121k | -81% | Mar 2024 |
|
Raymond James & Associates | 24k | $120k | 100% | Mar 2024 |
|
Landscape Capital Management | 21k | $107k | 100% | Mar 2024 |
|
Raymond James Financial Services Advisors | 17k | $87k | 100% | Mar 2024 |
|
Susquehanna Fundamental Investments | 16k | $82k | 100% | Mar 2024 |
|
DLK Investment Management | 16k | $82k | 0% | Mar 2024 |
|
Beacon Capital Management | 16k | $79k | 0% | Mar 2024 |
|
Charles Schwab Investment Management | 15k | $73k | 0% | Mar 2024 |
|
XTX Topco | 12k | $63k | 100% | Mar 2024 |
|
Bank of America Corporation | 11k | $58k | -80% | Mar 2024 |
|
Occudo Quantitative Strategies | 11k | $56k | -39% | Mar 2024 |
|
CTC Alternative Strategies | 11k | $56k | 100% | Mar 2024 |
|
Sherbrooke Park Advisers | 11k | $55k | 100% | Mar 2024 |
|
LMR Partners | 10k | $53k | 100% | Mar 2024 |
|
Palumbo Wealth Management | 10k | $52k | 100% | Mar 2024 |
|
Jpmorgan Chase & Co | 9.5k | $48k | -99% | Mar 2024 |
|
Simplex Trading | 7.5k | $37k | 3215% | Mar 2024 |
|
Tower Research Capital | 5.2k | $26k | -34% | Mar 2024 |
|
UBS Group | 4.3k | $22k | 7% | Mar 2024 |
|
Steward Partners Investment Advisory | 3.3k | $17k | 225% | Mar 2024 |
|
Federated Investors | 2.7k | $7.5k | -48% | Dec 2023 |
|
Group One Trading | 1.2k | $6.3k | 100% | Mar 2024 |
|
Pnc Financial Services | 1.0k | $5.1k | 0% | Mar 2024 |
|
Cutler | 700.00 | $3.0k | 17% | Mar 2024 |
|
Advisor Group Holdings | 568.00 | $2.9k | 0% | Mar 2024 |
|
Rhumbline Advisers | 449.00 | $2.3k | 0% | Mar 2024 |
|
IFP Advisors | 300.00 | $843.000000 | 0% | Dec 2023 |
|
Federation des caisses Desjardins du Quebec | 280.00 | $1.4k | 100% | Mar 2024 |
|
Wells Fargo & Company | 279.00 | $1.4k | 2% | Mar 2024 |
|
TSFG | 100.00 | $1.0k | 0% | Mar 2024 |
|
Goss Wealth Management | 17.00 | $85.999600 | 0% | Mar 2024 |
|
CWM | 9.00 | $0 | 0% | Mar 2024 |
|
Who sold out of Black Diamond Therapeutics?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Ikarian Capital | Dec 2023 | 556k | $1.6M |
Candriam Luxembourg S.C.A. | Dec 2023 | 540k | $1.5M |
Parkman Healthcare Partners | Sep 2023 | 521k | $1.5M |
Eudaimonia Asset Management | Sep 2023 | 207k | $595k |
Boothbay Fund Management | Sep 2023 | 120k | $344k |
Graham Capital Management | Dec 2023 | 86k | $241k |
Schonfeld Strategic Advisors | Dec 2023 | 81k | $228k |
683 Capital Management | Dec 2023 | 70k | $198k |
Marshall Wace | Dec 2023 | 23k | $64k |
Algert Coldiron Investors | Sep 2023 | 20k | $57k |
AE Wealth Management | Dec 2023 | 16k | $46k |
Herbst Group | Dec 2023 | 14k | $38k |
Belvedere Trading | Sep 2023 | 11k | $32k |
Royal Bank of Canada | Dec 2023 | 2.9k | $8.0k |
Advisory Services Network | Dec 2023 | 100.00 | $281.000000 |